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ABSTRACT 
ENGINEERING SPORES TO DISPLAY G PROTEIN-COUPLED RECEPTORS 
FOR DIRECTED EVOLUTION 
by 
Alyssa Misoo Kim 
All human cells are surrounded by a plasma membrane made from a phospholipid 
bilayer, which is responsible for maintaining a biologically active species, while stopping 
entry of deleterious substances from the outside. G protein-coupled receptors (GPCRs) 
are the membrane proteins, which transmit signals across the cell membrane. GPCRs are 
involved in almost every physiological process, and irregular control leads to 
pathological conditions. Therefore, they are major drug targets. Crystal structure 
determination is required to understand the molecular details of activation/deactivation. 
However, GPCRs are difficult to crystallize because of stability issues. An efficient 
protein engineering system needs to be developed. The goal is to design and create a 
system to display a heterologous protein on the Bacillus subtilis spore coat. Human 
parathyroid hormone receptor (huPTH1R) is used as a model system. HuPTH1R is a 
GPCR, which is vital in regulating calcium and phosphate levels in the blood. 
 Molecular biology is used to create the plasmid pDG1730 huPTH1R-CotC that 
fused huPTH1R to a spore coat protein, CotC. The plasmid is transformed into B. subtilis, 
and huPTH1R is successfully integrated into B. subtilis genome via recombination. This 
work represents the first system for GPCR display on the spore coat. Spore display 
overcomes many of the hurdles found in “traditional” protein display systems. Finally, 
this system can be used as a general method for engineering and optimizing membrane 
proteins by directed evolution. 
ENGINEERING SPORES TO DISPLAY G PROTEIN-COUPLED RECEPTORS 
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CHAPTER 1  
INTRODUCTION 
1.1 G Protein-Coupled Receptors 
G protein-coupled receptors (GPCRs) are integral membrane proteins characterized by 
seven transmembrane helices (TM) connected by three extracellular loops (ECLs) and 
three intracellular loops (ICLs) (1, 2) (Figure. 1.1).  
 
Figure 1.1  General structure of G protein-coupled receptors embedded in a lipid bilayer. 
 
 They are the largest family of membrane proteins in the human genome and 
function as the receptors for hormones, neurotransmitters, protons, ions, light, odors and 
gustative molecules (2). Thus, they are essential for communication between internal and 
external environments of cells. For example, the human β2 adrenergic receptor binds to 
adrenalin and noradrenalin on the exterior of the cell, and it leads to activate stimulation 
and regulation of the sympathetic nervous system. 
 GPCRs are involved in almost every physiological process. Hence, irregular 
control leads to pathological conditions, which include cancer, cardiovascular, metabolic, 
central nervous system and infectious diseases (1). As a result, GPCRs are major human 
 





drug targets. There are approximately 80 GPCR-targeting drugs in the current 
pharmaceutical market with annual sales reaching up to $50 billion, and they make 
approximately 30-50% of the drug targets (1). Notable examples are Eli Lilly’s Zyprexa 
(schizophrenia), Schering-Plough’s Clarinex (hay fever and allergy symptoms), 
GlaxoSmithKline’s Zantac (gastroesophageal reflux disease), and Novartis’s Zelnorm 
(irritable bowel syndrome). Therefore, crystal structure determination would provide 
molecular details of activation and deactivation, which would have an enormous impact 
in drug discovery. 
 GPCRs are divided into five families based on their sequence and structural 
similarity: rhodopsin (Class A or Family 1), secretin/adhesion (Class B or Family 2), 
glutamate (Class C or Family 3), Frizzled and Taste2 (1-3). The rhodopsin family is the 
largest and most diverse family among these families. There are four subfamilies in this 
diverse family: α, β, γ, δ. The α subfamily receptors activate the protons in retinal to 
detect the light. The β subfamily receptors, which include endothelin, 
gonadotropin-releasing hormone and oxytocin receptor ligands, bind to peptides. The γ 
subfamily consists of peptides or lipid-like receptors. Examples include somatostatin 
receptor 2 and 5, angiotensin receptor 1, and chemokine receptors, which are drug targets 
in this group. The δ subfamily is responsible for olfactory. The secretin family receptors 
bind peptide hormones like calcitonin, glucagon and parathyroid hormone. These 
hormones are used to regulate hypercalcaemia, hypoglycaemia and osteoporosis. In the 
glutamate family, there are four kinds of receptors that include metabotropic glutamate, 
GABAB, sweet and umami taste, and calcium sensing. These three main families can be 




and smoothened receptors involved in embrogenesis. The frizzled receptors bind Wnt 
glycoproteins, whereas smoothened receptors perform as the signaling unit. Last, Taste2 
family consists of taste receptors including bitter sensing.  
1.2 Crystal Structure and Problems 
To date, there are only eight different crystal structures for GPCRs, which include 
rhodopsin (4, 5), β2AR (6), β1AR (7), adenosine A2A receptor (ADORA2A) (8), histamine H1 
(9), sphingosine 1-phosphate (10), and CXCR4 chemokine receptor (11). Despite huge 
research efforts in GPCR crystallography, determination of GPCRs structure is difficult 
due to the protein properties.  
 A protein needs to be functionally expressed, purified, and crystallized in order to 
successfully solve the crystal structure. However, there are several problems to determine 
the crystal structure of GPCRs. First, GPCR expression in native tissue is typically very 
low (12); therefore, GPCRs need a recombinant expression system. GPCRs can be 
overexpress in prokaryotic system such as Escherichia coli. However, they are expressed 
as insoluble inclusion bodies. As a result, they must be solubilized and refolded using 
detergents and other chemical additives. Next, compared to soluble or cytoplasmic 
proteins, membrane proteins are difficult to crystallize because they are found in a lipid 
bilayer. This environment is difficult to mimic during the crystallization procedure. In the 
early 1980s, detergent-based micelles were designed to solubilize membrane proteins. In 
addition, bilayer vesicles, lipidic mesophase approaches, and lipid/detergent procedures 
were used to assist crystallization. Finally, GPCRs typically have thermodynamic and 
proteolytic protein stability problems (12). As a result, there is a lack of secondary 




 The first GPCR structure was bovine rhodopsin (Figure. 1.2). This crystal 
structure has provided useful information for activation mechanism of GPCRs. 
Rhodopsin was more suitable for structural studies than most of other GPCRs because it 
can be obtained large quantities of functional protein from retinas, and they are thermally 
stable compared to other GPCRs.  
 
Figure 1.2  Structure of rhodopsin (PDB ID: 3PQR) (13). 
 
 In order to improve proteolytic stability, several protein engineering efforts have 
been employed. Recently, crystal structures of the human β2 adrenocepter (β2AR) as a 
receptor for adrenalin and noradrenalin have been determined. β2AR was the first 
non-rhodopsin GPCR to be cloned and was one of the most extensively studied members. 
Two different protein engineering strategies were utilized. First, β2AR was stabilized by 
binding a stable antibody fragment (Fab5) to the unstructured cytoplasmic ends of TM5 




the unstructured ICL3 sequence from Q230 to S262 was replaced with structured protein, 
T4 lysozyme (T4L) (14) (Figure. 1.4). In essence, a stable protein (antibody or lysozyme) 
was associated with the unstable GPCRs to impact an overall stable structure. In addition, 
β1AR and β2AR were further stabilized by addition of stabilizing ligands, amino acid 
substitutions, adding lipids, and high salt concentrations. 
 



















Figure 1.4  Structure of β2AR-T4 lysozyme fusion (14) (PDB ID of β2AR-T4 lysozyme: 
2RH1(15) and T4 lysozyme: 206L(16)). 
 
 There are still no crystal structures for most of the rhodopsin family and other 
GPCR families such as the gamma-aminobutyric acid (GABA) or the metabotropic 
glutamate receptors (mGluRs) in family 3.  
1.3 Directed Evolution  
Darwinists believe the diversity found on Earth is due to evolution (17). Evolution does 
not go toward a specific objective. It moves by random changes and it alters the capacity 
of an organism to reproduce under the present conditions. An adapted organism to the 













evolution requires a bit of “sloppiness”. This allows an organism to adapt to unexpected 
changes in the environment. Furthermore, evolution is based on the past. New structures 
and metabolic functions are created from pre-existing elements. Finally, evolution does 
not end, and does not go towards absolute complexity. We hold that human beings are at 
the top of the evolutionary scheme. However, a quick scan of the diversity of organisms 
shows that simpler ones have not been extinct or stopped evolving. The timescale of 
months to years can occur for natural evolution. One example is the appearance of 
antibiotic resistant bacteria and enzymes that degrade chemically synthesized compounds 
(18, 19). 
 The products of evolution occur on many different levels. It is responsible for the 
diversity of life. In addition, evolution can be seen all the way down to single molecules 
such as proteins. For example, human ribonuclease and angiogenin share similar tertiary 
structures (Figure. 1.5). However, they have completely different functions. Ribonuclease 





Figure 1.5  (A) Human ribonuclease (PDB ID: 5RSA) (20). (B) Angiogenin (PDB ID: 
1B1I) (21). (C) Paralogs that perform different functions in one organism. 
 
 Protein engineering strategies can be roughly categorized as rational or 
evolutionary. Rational design requires detailed information of the protein structure and 
function. Guided by the structure, individual amino acids are chosen for substitution in 
order to modify the function. This is usually done by site directed mutagenesis (22). Site 
directed mutagenesis is a molecular biology method. A specific nucleotide in the DNA is 
mutated, which results in change in an amino acid. Some successes include increased 
thermostability (23-26), altered substrate specificity (27), and introducing post translation 
modification (28). The main disadvantage of rational design is the effect of the amino acid 














how the changes affect every aspect of the protein. For example, we may be able to 
introduce a new function, such as altered substrate specificity. However, it is impossible 
to forecast the cost that the substitution has on a different property, such as 
thermostability. In conclusion, we need a huge amount of structural, mechanistic, and 
dynamic knowledge for a successful rational design effort. This information is only 
known for a small fraction of proteins. 
 On the other hand, directed evolution is a method that mimics the process of 
natural evolution in order to create mutants with novel and desired properties. The 
greatest advantage is that a detailed knowledge of structure or mechanism is not required. 
Directed evolution experiment has iterative cycles (Figure. 1.6). First, a library of genes 
up to 1015 members is generated by molecular biology techniques. Second, the DNA 
library is introduced into a suitable host. Typically, a library has 104-109 variants of the 
parent. Third, proteins from the library with improved functions are identified by 
appropriate screening or selection methods. Finally, the genes are used as parents for the 
next round of directed evolution. Through these repeated cycles, useful and desired 
mutations can accumulate like the natural evolution process. To name a few examples, 
directed evolution has been used to alter substrate specificity, increase thermal stability, 





Figure 1.6  Basic steps of a directed evolution experiment. First, a library of genes is 
created. The library of variants is up to 1015. Next, the library is cloned in an expression 
vector and transformed in a host cell. The desired proteins are screened or selected from 
the library. Finally, the improved proteins are used as parents for next round of evolution. 
(PDB ID: 3PQR) (13) 
 
 There are several techniques used to create libraries. As an example, the most 
common and successful methods are random mutagenesis, cassette mutagenesis, and in 
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1.4 Protein Display 
In nature, proteins localized on the cell surface are important to function. For example, 
they perform fundamental biological functions, including transportation such as 
importing and exporting molecules, adhesion molecules and receptors, communication 
between cells, signal transduction, and others (33). Now, molecular biology has made it 
possible to use these cell surface proteins for biotechnological application. For example, 
microbial cell-surface display can be used to express a heterologous protein of interest as 
a fusion with various anchoring motifs as carrier proteins. Applications include peptide 
library screening (34-36), directed evolution of proteins (34, 35), vaccines development and 
targeted therapies (36-38), biocatalyst (36, 39), bioadsorption (36), mutation detection (36), 
biosensors (36), and bioremediation (34).   
 “Traditional” microorganisms used for protein display are phage (40), prokaryotes 
(33), and yeast (34, 41). Protein display has several advantages when compared to libraries 
expressed in the cytoplasm (Figure. 1.7). For libraries expressed in the cytoplasm, a 
microtiter plate procedure may be needed to assay protein function. In a typical round of 
evolution, up to 103-104 protein variants can be conveniently assayed. Cells are usually 
arrayed in microtiter plates and they must be lysed to gain access to the protein. In this 
step, the genotype/phenotype connection is disconnected. Next, the cell debris may be 
required to be separated from the lysate. This step oftentimes necessitates multiple 
centrifugation and pipetting steps, which needs automated robotic systems. Furthermore, 
the lysate is a complex solution containing the target protein and the contents of the 





Figure 1.7  (A) Proteins (Blue) which are expressed inside the host cell. (B) Proteins 
(Blue) which are displayed outside the host cell. 
 
 Protein display can overcome the obstacles presented above. First, the protein is 
freely accessible and assayed easily. Next, multiple liquid handling steps are not 
necessary because the cells are not lysed. Furthermore, the environment for screening 
such as pH, buffer composition, and ionic strength can be easily controlled. Finally, the 
genotype/phenotype remains intact. 
 A directed evolution strategy begins with determination of a suitable surface 
display platform (phage, prokaryote or yeast), based on characteristics of the protein. 
Gene libraries of the protein are created by random mutagenesis and/or recombination. 
Cloned genes are inserted into plasmid. They are transformed into a host and induced. 
Each cell has an individual member of the library on the cell surface, and screened for 
function. Next, the cells are cultured, the gene is isolated, and another round of evolution 
can be done (Figure. 1.8). 
 





Figure 1.8  Protein screening of mutant libraries displayed the cell surface. 
 
1.4.1 Phage Display 
Bacteriophage is a virus that infects bacteria. Filamentous phage display was the first 
system, which was developed by George P. Smith, and it remains the most common. A 
peptide of interest can be fused with the pIII protein (Figure. 1.9) (42, 43). T4 (39, 44, 45), T7 
(39, 44), and λ phage (39, 44, 46) have also been used. Phage display has been used engineer 
antibodies (47, 48), discovery drug-like molecules (49), and molecular biomimetics (50). In 











Figure 1.9  Phage display. A foreign protein of interest is fused with the pIII protein. 
 
 An advantage of phage display is that it is easy to perform and inexpensive. A 
library size of 1010 can be screened in a single day. Usually, three to five cycles are 
enough to generate peptide sequences with high binding efficiency. However, the size of 
the foreign protein to be displayed on the surface of phage is rather limited.  
1.4.2 Microbial Cell Surface Display 
Functional enzymes, peptides libraries, and antibody fragments have been displayed on 
the cell surfaces of bacteria (34). There are two microbial cell surface display systems, 
gram-negative and positive. First, the architecture of gram-negative bacteria membrane 
includes an inner membrane and outer membrane, and sandwiched between the two is a 
peptidoglycan structure. Outer membrane proteins have been used as carriers to display 
foreign proteins on the surface (Figure. 1.10). Foreign genes can be fused to outer 
















Figure 1.10  Gram-negative bacteria cell surface display. 
 
 Secondly, gram-positive bacteria such as Staphylococcus xylosus or 
Staphylococcus carnosus have been used. They have a thicker cell wall and lack the outer 
membrane (Figure. 1.11). They are more suitable to apply for cell catalysts and 
adsorbents because of cell wall rigidity. Bacillus and Staphylococcus strains have been 
commonly used. 
 

























 Library sizes of 109-1011 can be obtained and screened. On the other hand, a 
major concern is a protein folding issue (vide infra). In addition, E. coli does not have the 
machinery capable of post-translational modifications, such as glycosylation, necessary 
for functional expression of eukaryotic proteins.  
1.4.3 Yeast Surface Display 
Yeast display has also been used to improve affinity, specificity, expression, stability, and 
catalytic activity for various foreign proteins (54). The Aga1-Aga2 protein complex in 
Saccharomyces cerevisiae has been used as anchors for protein display (Figure. 1.12). 
These proteins are covalently connected to the cell wall (41, 55). This display system has 
been utilized for presentation of various proteins such as green fluorescent protein (GFP), 
blue fluorescent protein (BFP), the hepatitis B virus antigen, and glucoamylase (56, 57).  
 
Figure 1.12  Yeast surface display. The surface displayed protein of interest is fused by 
its N-terminus to the C-terminus of Aga2 protein.   
 
 There are several advantages in yeast surface display for protein engineering. 
Yeast can display large proteins up to 500 amino acids; whereas, a filamentous phage is 
limited to small peptides. Yeast can perform post-translational modifications. Hence, they 














protein folding (54). On the other hand, a potential drawback of yeast surface display is the 
smaller library size of 106-107, which is due to low transformation efficiency. 
Furthermore, protein folding can be a problem (vide infra).  
1.4.4 Ribosome Display 
Ribosome display is cell free evolution technology to create proteins libraries (Figure. 
1.13). The DNA library contains all the signals for transcription and translation. In 
ribosome display, the translated protein remains connected to the ribosome because there 
is no stop codon. As a result, a ternary complex of mRNA, ribosome, and protein produce 
is used for selection (58). 
 
Figure 1.13  Ribosome display for screening for protein libraries. Step 1. DNA library 
contains the T7 promoter, ribosome binding site, and stem-loops. Step 2. The mRNA is 
translated. Translation is stopped by cooling to 4°C, and the protein is screened for 
function. Step 3. Libraries are screened. Step 4. The mRNA is isolated. Step 5. The 


















 Ribosome display has been used to screen antibody libraries (59), peptides (60), 
proteins with increased stability (61). An advantage of ribosome display is that large 
libraries up to 1012-1013 can be screened. However, there are some issues, which include 
protein misfolding, instability mRNA-ribosome-protein complex, and disulfide bonds 
formation (62). 
1.4.5 mRNA Display   
Another in vitro evolution technology is mRNA display for protein and peptide selections 
(Figure. 1.14).  
 Like ribosome display, mRNA display produces libraries up to 1012-1013. As a 
result, rare sequences can be identified. The mRNA display system has advantage over 
the ribosome display. The covalent mRNA-protein complex linked by puromycin has 
resistance to harsh environments. A shortcoming of mRNA display is purification of the 
protein-puromycin-DNA-mRNA from the ribosome (62).  
 The mRNA display technique has been used to create libraries of heavy domains 
and single-chain antibodies as well as select linear and constrained peptides (62). 
Furthermore, selections in mRNA display system can identify polypeptide substrates (63) 






Figure 1.14  mRNA display. Step 1. The DNA library is transcribed to mRNA. Step 2. 
Puromycin is linked to the mRNA. Step 3. Translation is done in vitro. Step 4. 
Translation is stopped at the linker region. Puromycin binds to the ribosome. Step 5. 
Protein is transferred to puromycin. Step 6. mRNA is transcribed. Step 7. Selection for 































1.4.6 Spore Display  
Protein display methods have revolutionized protein engineering in academic and 
industrial settings. However, these technologies suffer several limitations, which have 
been discussed above. More importantly, there are two significant issues; protein folding 
and cell viability. Initially, protein must be folded properly for function. In E. coli display, 
the protein is expressed in cytoplasm, which has a reducing environment. This hinders 
correct disulfide bond formation. In addition, the unfolded peptide must cross the inner 
membrane, peptidoglycan layer, and the outer membrane. Again, protein folding is a 
concern. Next, screening proteins for extreme properties, such as organic solvent 
resistance or thermal stability, will destroy the cell. This will also occur when assaying 
with toxic substrates. As a result, the microorganism cannot be cultured, and the 
genotype/phenotype connection will be lost.  
 Spore display may solve protein folding and cell viability issues. Protein folding 
concerns may be bypassed due to the natural sporulation process (65) (Figure. 1.15). First, 
the vegetative cell divides into two compartments, the mother cell and forespore. The 
mother cell nurtures the formation of the spore. Spore coat proteins are synthesized in the 
mother cell and they are deposited to form the coat. In short, proteins found on the 
surface of the spore do not have to cross membranes. In addition, the mother cell contains 





Figure 1.15  Sporulation in Bacillus Subtilis. 
 
 Second, they are capable of enduring harsh physical and chemical conditions such 
as heat, radiation, ultraviolet, desiccation, and oxidizers. Spores remain viable under 
these conditions, while microorganism such as yeast and E. coli cannot. As a result, 
screening protein with extreme properties can be achieved, and the genotype/phenotype 
connection remains intact. 
 Spore display may also have additional advantages. In general, immobilized 
proteins (66) have some economical and technological benefits. They are separated easily 
from the reaction mixture, and the protein stability is increased. For protein 
immobilization, it is typically expressed, purified, and attached to an inert material. 
However, proteins are “pre-immobilized” during the sporulation process. 
 Surface display on B. subtilis has been used in biotechnological and 
pharmaceutical applications (36) such as vaccines, biosensors, whole cell catalysts, and 










suitable platform for directed evolution (67). B. subtilis is convenient organism for protein 
display. The genome is known and they can be easily manipulated with molecular 
biology techniques. Furthermore, spores can be easily produced in large quantities. Lastly, 
they are safe to use and have been developed as additives for foods and drugs.  
Spore Display of G-Protein Coupled Receptors: Human Parathyroid Hormone 
Receptor 1 (huPTH1R)  
As mentioned above, obtaining high-resolution crystal structures is a major obstacle 
towards understanding the molecular mechanisms of GPCR constitutive activity and 
activation. One significant challenge is acquiring a sufficient amount of protein to 
crystallize because most GPCRs are expressed at low levels in native tissue. Hence, a 
suitable recombinant expression system must be developed to produce correctly folded 
protein, and insect and COS-1 mammalian cells have been used for this purpose (68). E. 
coli has been also used to generate GPCRs (68). However, the proteins are expressed as 
inclusion bodies and they require detergents and other chemical additives for 
solubilization and refolding. 
 Spore display offers the opportunity to employ directed evolution methods to 
stabilize GPCRs. This evolutionary approach would complement other stability methods, 
such as antibodies binding (6, 14), T4 lysozyme grafting (14, 15), and other protein 
engineering efforts were also used. One notable example was the evolution of GPCRs for 
higher expression and stability, which was achieved in two steps (69). First, a library of 
GPCRs was expressed in the inner membrane of E. coli, and GPCRs with increased 
expression level were sorted with Fluorescence-Activated Cell Sorting, FACS. Second, 




clones were expressed and tagged with biotin, and then they were partially purified using 
streptavidin coated magnetic beads. Finally, they were assayed for enhanced thermal 
stability. 
 Spore display of GPCRs may be a general tool for engineering these proteins by 
overcoming several concerns. First, spore display results in “purified” protein on the 
spore surface because each spore will contain a unique member of the library. Next, the 
displayed GPCRs are expected to be unfolded and they need to be solubilized and 
refolded.  As mentioned above, this step requires detergents and other chemical additives. 
Spores can endure extreme environments and they still remain viable. Hence, spores are 
not affected during the refolding process. On the other hand, the refolding conditions are 
not compatible for the more established protein display formats, such as E. coli and yeast, 
because the cell wall may rupture. This would result losing in the genotype/phenotype 
connection. Finally, only the GPCRs that can be expressed and assayed will be displayed. 
For example, GPCRs with rare codon usage in B. subtilis may be removed during the 
library creation and screening procedure. In short, spore display can be a general tool to 
engineer proteins. 
 The goal of this project is to design and create a system for spore display. The 
molecular biology will be performed in order to fuse a GPCR, human parathyroid 
hormone receptor 1 (huPTH1R), to the spore coat protein, CotC. HuPTH1R is vital in 
regulating calcium and phosphate levels in the blood (70). Defects in huPTH1R can result 




CHAPTER 2  
DESIGNING A SYSTEM FOR DISPLAYING HUMAN PARATHYROID 
HORMONE RECEPTOR 1 ON THE SPORE COAT OF BACILLUS SUBTILIS 
 
In this chapter, the design is described for the construction of a system to display 
G-protein coupled receptors on spore coat of Bacillus subtilis. More specifically, the 
cloning design and molecular biology will be outlined. 
2.1 Materials 
Analytical regent grade chemicals were purchased from Sigma-Aldrich (St. Louis, MO), 
BD (Franklin Lakes, NJ), Research Products International Corp. (Mount Prospect, IL), 
and Invitrogen (Carlsbad, CA). Restriction enzymes were purchased from Invitrogen 
(Carlsbad, CA) and New England Biolabs (Ipswich, MA). T4 DNA ligase and Taq DNA 
polymerase were from Invitrogen (Carlsbad, CA), and PfuUltra HF DNA polymerase 
was from Ailgent technologies (Santa Clara, CA). Primers were procured from Eurofins 
MWG Operon (Huntsville, AL). QuikChange Site-Directed Mutagenesis Kit was 
purchased from Ailgent technologies (Santa Clara, CA). QIAprep spin miniprep kit, 
QIAquick PCR Purification Kit, and QIAquick gel extraction kit were purchased from 
Qiagen (Valencia, CA). DNA sequencing was performed at Molecular Resource Facility 





2.2.1 Remove XhoI Restriction Site at Position 7049 Base Pair for Ease of Cloning 
The PCR reaction mixture consist of 5µl of 10X reaction buffer, 5 to 50ng template, 
pDG1730 GFP-CotC, 125ng of pDG1730 XhoI forward (pDG1730 XhoI-F: 
5'-GGAAGTATCCAGCTCCAGGTCGGGCCGCG-3') and pDG1730 XhoI reverse 
primer (pDG1730 XhoI-R: 5'-CGCGGCCCGACCTGGAGCTGGATACTTCC-3'), 
respectively, 1µl of dNTP mix and ddH2O to a final volume of 50µl. Then, 1µl pfuTurbo 
DNA polymerase (2.5U/µl) was added. The PCR consisted of 1 cycle at 95°C for 30 
seconds and 12 cycles at 95°C for 30 seconds, 55°C for 1 minute and 68°C for 4 minutes. 
After the PCR reaction, the product were directly digested with 1µl  of the DpnI 
restriction enzyme (10U/µl), and incubated at 37°C for an hour. After digestion, it was 
transformed into XL1-Blue supercompetent cells by heat shock. The transformed cells 
were plated on the Luria–Bertani (LB) plate containing ampicillin (50µg/mL) and 
incubated at 37°C overnight. The mutated plasmid was isolated using QIAprep spin 
miniprep kit, and both original and mutated plasmids were digested with XhoI and EcoRI 
to check and compare the results. The mutation was verified by agarose gel 
electrophoresis.  
2.2.2 Amplification of Human Parathyroid Hormone Receptor 1 
Human parathyroid hormone receptor 1 (huPTH1R) was amplified from the plasmid 
pET15b huPTH1R (Aline Desmyster, Architecture et Fonction des Macromolécules 
Biologiques, UMR 6098, CNRS, and Universités of Marseille, F-13288 Marseille Cedex 




of dNTP mix, 100ng/µl of pET15b – huPTH1R template, 100ng/µl each of huPTH1R – 
HindIII-F (5'-GGCAAGCTTACATAAGGAGGAACTACTATGGGCAGCAGCCATC 
ATC-3') and huPTH1R – XhoI-R (5'-CGGCTCGAGCATGACTGTCTCCCACTCTTCC 
-3'), 1µl of PfuUltra HF DNA polymerase (2.5U/µl), and up to 50µl with sterile ddH2O. 
The PCR consisted of 1 cycle at 95°C for 2 minutes, 30 cycles at 95°C for 30 seconds, 
65°C for 30 seconds and 72°C for 4 minutes, and then 1 cycle 72°C for 10 minutes. The 
PCR amplification products were purified using QIAquick PCR Purification Kit and 
analyzed on a 1% (w/v) agarose gel. 
2.2.3 Construction of pDG1730 HuPTH1R-CotC 
2.2.3.1 Digestion of pDG1730 GFP-CotC and HuPTH1R PCR Fragments. The 
reaction mixture contained HindIII, 10X buffer, each of pDG1730 GFP-CotC or 
huPTH1R PCR fragments from above, and to a final volume 50µl. Both mixtures were 
incubated at 37°C for 3 hours. The digested pDG1730 GFP-CotC and huPTH1R 
fragments were purified using QIAquick PCR Purification, and then second digestion 
with XhoI was performed. The reaction mixture included XhoI, 10X buffer, digested 
pDG1730 GFP-CotC and huPTH1R PCR fragments, respectively, and up to 50µl with 
sterile ddH2O. Incubation conditions were at 37°C for 3 hours again. Finally, the products 
were purified using QIAquick gel extraction kit to select desired size of fragments. 
2.2.3.2 Ligation of HuPTH1R and pDG1730 CotC. Purified huPTH1R (insert) 
and pDG1730 (vector) were ligated (Figure. 2.1 A). The 20µl ligation reaction contained 




T4 DNA ligase. The ligation was performed at 25°C for 1 hour. The final plasmid 
construct, pDG1730 huPTH1R-CotC (Figure. 2.1 B), was created. 
 
Figure 2.1  Plasmid maps. (A) pDG1730. (B) pDG1730 huPTH1R-CotC. Genes; amyE’: 
encodes front of α-amylase; ‘amyE: encodes back of α-amylase; spc: encodes 
spectinomycin adenyltransferase (spectinomycin resistance); bla: encodes β-lactamase 
(ampicillin resistance); erm: encodes rRNA adenine N-6-methyltransferase 
(erythromycin resistance). BamHI, HindIII, EcoRI and XhoI are the restriction sites. 
 
2.2.3.3 Transformation of pDG1730 huPTH1R-CotC. The ligated plasmid was 
transformed into XL10-gold ultracompetent cells by electroporation. The transformed 
cells were spread on the LB agar plate containing ampicillin (50µg/mL), and incubated at 
37°C overnight. The plasmid was isolated using QIAprep spin miniprep kit. The insert 




































































































































2.2.4 Bacillus subtilis Transformation  
The plasmid pDG1730 huPTH1R-CotC was linearized by digestion with SpeI at 37°C for 
3 hours and used to transform competent cells of the CotC knockout B. subtilis strain 
(Figure. 2.3). The B. subtilis cells were plated on the LB agar plate containing 
spectinomycin (100µg/mL) and chloramphenicol (5µg/mL), and then they were incubated 
at 37°C overnight. The plasmid pDG1730 huPTH1R-CotC was integrated into the 
non-essential amyE gene by double crossover recombination. This integration was 
verified using PCR and the primers used were huPTH1R – HindIII-F and huPTH1R – 
XhoI-R. The reaction and cycling condition was the same as for the amplification of 
huPTH1R. Next, wild-type B. subtilis and B. subtilis transformed with pDG1730 
huPTH1R-CotC were spread on the LB agar plate containing spectinomycin (100µg/mL) 
and analyzed by growth on the plate with appropriate antibiotics. Finally, genomic DNA 





Figure 2.3  Integration of pDG1730 huPTH1R-CotC into Bacillus subtilis genome.  
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CHAPTER 3  
RESULTS AND DISCUSSION 
3.1 Remove XhoI Restriction Site at Position 7049 Base Pair for Ease of Cloning 
The plasmid pDG1730 GFP-CotC (Patrick Eichenberger, Department of Biology, New 
York University) contains two XhoI restriction sites (CTCGAG). A guanine to cytosine 
point mutation was performed at position 7049 using QuikChange Site-Directed 
Mutagenesis. It was necessary to have only one XhoI restriction site for ease of cloning. 
To verify the result of removing XhoI restriction site, the plasmid pDG1730 GFP-CotC 
and the mutated plasmid was digested with XhoI and EcoRI (Figure. 3.1).   
 The pDG1730 GFP-CotC and the mutated plasmids were digested with EcoRI. It 
is expected to generate one linear fragment, 8903bp (Figure. 3.1, Lanes 2 and 3) because 
there is only one restriction site. On the other hand, the plasmid pDG1730 GFP-CotC was 
digested with XhoI. It is expected to result in two fragments, 5308 bp and 3595 bp 
(Figure. 3.1, Lanes 4). The mutated plasmid has only one XhoI restriction site, and the 





Figure 3.1  Analysis of mutation of XhoI restriction site by gel electrophoresis. Lane 1: 
1kb DNA plus ladder, Lane 2: EcoRI digestion of pDG1730 GFP-CotC original plasmid, 
Lane 3: EcoRI digestion of QuikChange site-directed mutation of pDG1730 GFP-CotC 
plasmid, Land 4: XhoI digestion of pDG1730 GFP-CotC original plasmid, Lane 5: XhoI 
digestion of QuikChange site-directed mutation of pDG1730 GFP-CotC plasmid. 
 
3.2 Amplification of Human Parathyroid Hormone Receptor 1 
The huPTH1R gene was successfully amplified from the plasmid pET15b huPTH1R 
(Aline Desmyster, Architecture et Fonction des Macromolécules Biologiques, UMR 
6098, CNRS, and Universités of Marseille, F-13288 Marseille Cedex 09, France) (68) with 
huPTH1R – HindIII-F and huPTH1R – XhoI-R, which were the forward and reverse 
primers, respectively. The forward primer incorporated a HindIII restriction site at the 5’ 
end, while the reverse primer integrated an XhoI restriction site at the 3’ end. The PCR 
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reaction was purified using QIAquick gel extraction kit, and PCR products were analyzed 
on the 1% (w/v) agarose gel. The expected size of huPTH1R was 1806bp (Figure. 3.2, 
Lane 3). 
 
Figure 3.2  Analysis of huPTH1R gene by gel electrophoresis. Lane 1: 1kb DNA plus 
ladder, Lane 2: pET15b huPTH1R original plasmid, Lane 3: huPTH1R PCR products. 
 
3.3 Construction of pDG1730 HuPTH1R-CotC 
The plasmid pDG1730 huPTH1R-CotC was constructed. First, the pDG1730 GFP-CotC 
and huPTH1R PCR product were digested with HindIII and XhoI. This created sticky 
ends in order to ligate the vector (digested pDG1730 GFP-CotC) and the insert (digested 
huPTH1R PCR product). The digestions were analyzed by agarose gel electrophoresis. 
The digested insert shows one band at 1806 bp (Figure. 3.3, Lane 3). 







Figure 3.3  Analysis of huPTH1R PCR fragments after XhoI digestion by gel 
electrophoresis. Lane 1: 1kb DNA plus ladder, Lane 2: pET15b huPTH1R original 
plasmid, Lane 3: huPTH1R PCR fragments. 
 
 The double digestion of pDG1730 GFP-CotC resulted in two bands. The band at 
738bp corresponds to the coding region for GFP, and the band at 8165 bp was remaining 











Figure 3.4  Analysis of pDG1730 GFP-CotC after XhoI digestion by gel electrophoresis. 
Lane 1: 1kb DNA plus ladder, Lanes 2 and 3: pDG1730 CotC and GFP, Lane 4: 
pDG1730 GFP-CotC original plasmid. 
 
 The vector and insert were cut out and purified from the gel using a QIAquick gel 
extraction kit. Separate ligation reactions were done with insert to vector ratio of 1:1, 3:1, 
6:1, and 9:1. Then, the ligated plasmids were transformed into XL10-gold ultracompetent 
cells by electroporation and plated on the LB agar plate containing ampicillin (50µg/mL). 
Several colonies were selected, and plasmids were isolated using QIAprep spin miniprep 
kit. Successful ligation was determined by PCR amplification of the insert, huPTH1R. A 
clone was found in the 3:1 insert to vector reaction, which displayed an 1806 bp fragment 
(Figure. 3.5, Lane 6). This plasmid was requested DNA sequencing (UMDNJ), and the 















Figure 3.5  Analysis of huPTH1R after transformation by gel electrophoresis. Lane 1: 
1kb DNA plus ladder, Lane 2: huPTH1R PCR products for positive control, Lane 3 ~ 6: 
huPTH1R PCR products after transformation. 
 
3.4 Bacillus subtilis Transformation 
The plasmid pDG1730 huPTH1R-CotC was linearized with the restriction enzyme SpeI, 
and it was transformed into competent cells of the CotC knockout B. subtilis strain. The 
B. subtilis cells were spread on the LB agar plate containing spectinomycin (100µg/mL) 
and chloramphenicol (5µg/mL). Several colonies were chosen, and the genomic DNA 
was isolated. PCR was performed with the genomic DNA, and a product corresponding 
with the correct size of huPTH1R PCR (1794 bp) was detected by agarose gel 






electrophoresis (Figure. 3.6, Lane 3). In addition, genomic DNA was isolated and 
sequenced (UMDNJ) for the presence of the huPTH1R gene (Appendix B).   
 
Figure 3.6  Analysis of recombination of pDG1730 huPTH1R CotC by gel 
electrophoresis. Lane 1: 1kb DNA plus ladder, Lane 2: huPTH1R PCR products for 
positive control, Lane 3: huPTH1R PCR products after B. subtilis transformation. 
 
 Next, integration of pDG1730 huPTH1R-CotC resulted in conferring antibiotic 
resistance to spectinomycin resistance. Wild type of B. subtilis did not grow on the LB 
agar plate containing spectinomycin (100µg/mL), while the transformed B. subtilis strain 
did (Figure. 3.7). 
 








Figure 3.7  Growth characteristics of B. subtilis with LB agar plates containing 
spectinomycin (100µg/mL). (A) Wild-type B. subtilis. (B) B. subtilis strain transformed 






CHAPTER 4  
CONCLUSION 
In conclusion, integration of huPTH1R into B. subtilis was successfully done. First, 
molecular biology was used to create the plasmid pDG1730 huPTH1R-CotC that fused a 
GPCR (huPTH1R) to a spore coat protein (CotC). Next, pDG1730 huPTH1R-CotC was 
transformed into B. subtilis display to integrate the GPCR into the genome. This work 
represents the first system for GPCR display on the spore coat. Spore display overcomes 
many of hurdles found in “typical” protein display systems. Furthermore, this system can 
be used a general method for engineering and optimizing membrane proteins by directed 
evolution. The next goals are to demonstrate proper GPCR display on the spore coat, and 







SEQUENCING ANALYSIS RESULTS  
Figure A.1 to A.8 show DNA sequencing results of pDG1730 huPTH1R-CotC. 
(A) 
 
Figure A.1  DNA sequencing results of pDG1730 huPTH1R-CotC. (A) Top strand is the 
DNA coding region from the promoter of CotC to CotC, PCotC-huPTH1R-CotC DNA. 
The bottom strand represents the DNA sequencing results using the primer seq-huPTH1R 
CotC-F1 (5’-TATGCCGCGATTTCCAATGAGG-3’). Nucleotide 641 is the start of PCotC 















Figure A.1  DNA sequencing results of pDG1730 huPTH1R-CotC. (B) DNA sequencing 









Figure A.2  DNA sequencing results of pDG1730 huPTH1R-CotC. (A) Top strand is the 
DNA coding region from the promoter of CotC to CotC, PCotC-huPTH1R-CotC DNA. 
The bottom strand represents the DNA sequencing results using the primer seq-huPTH1R 
CotC-F2 (5’-GGCAAGCTTACATAAGGAGGAACTACTATGGGCAGCAGCCATCA 
TC-3’). Nucleotide 641 is the start of PCotC and 3015 is end of CotC. This alignment 

















Figure A.2  DNA sequencing results of pDG1730 huPTH1R-CotC. (B) DNA sequencing 









Figure A.3  DNA sequencing results of pDG1730 huPTH1R-CotC. (A) Top strand is the 
DNA coding region from the promoter of CotC to CotC, PCotC-huPTH1R-CotC DNA. 
The bottom strand represents the DNA sequencing results using the primer seq-huPTH1R 
CotC-F3 (5’-CACAACAGGACGTGGGCCAACTACAG-3’). Nucleotide 641 is the start 


















Figure A.3  DNA sequencing results of pDG1730 huPTH1R-CotC. (B) DNA sequencing 









Figure A.4  DNA sequencing results of pDG1730 huPTH1R-CotC. (A) Top strand is the 
DNA coding region from the promoter of CotC to CotC, PCotC-huPTH1R-CotC DNA. 
The bottom strand represents the DNA sequencing results using the primer seq-huPTH1R 
CotC-F4 (5’-GGCCACCAACTACTACTGGATTCTGG-3’). Nucleotide 641 is the start 



















Figure A.4  DNA sequencing results of pDG1730 huPTH1R-CotC. (B) DNA sequencing 













Figure A.5  DNA sequencing results of pDG1730 huPTH1R-CotC. (A) Top strand is the 
DNA coding region from the promoter of CotC to CotC, PCotC-huPTH1R-CotC DNA. 
The bottom strand represents the DNA sequencing results using the primer seq-huPTH1R 
CotC-F5 (5’-GCAATGGCGAGGTACAAGCTGAGATC-3’). Nucleotide 641 is the start 




















Figure A.5  DNA sequencing results of pDG1730 huPTH1R-CotC. (B) DNA sequencing 
















Figure A.6  DNA sequencing results of pDG1730 huPTH1R-CotC. (A) Top strand is the 
DNA coding region from the promoter of CotC to CotC, PCotC-huPTH1R-CotC DNA. 
The bottom strand represents the DNA sequencing results using the primer seq-huPTH1R 
CotC-R2 (5’-CGGCTCGAGCATGACTGTCTCCCACTCTTCC-3’). Nucleotide 641 is 


















Figure A.6  DNA sequencing results of pDG1730 huPTH1R-CotC. (B) DNA sequencing 









Figure A.7  DNA sequencing results of pDG1730 huPTH1R-CotC. (A) Top strand is the 
DNA coding region from the promoter of CotC to CotC, PCotC-huPTH1R-CotC DNA. 
The bottom strand represents the DNA sequencing results using the primer seq-huPTH1R 
CotC-R4 (5’-CCAGAATCCAGTAGTAGTTGGTGGCC-3’). Nucleotide 641 is the start 


















Figure A.7  DNA sequencing results of pDG1730 huPTH1R-CotC. (B) DNA sequencing 













Figure A.8  DNA sequencing results of pDG1730 huPTH1R-CotC. (A) Top strand is the 
DNA coding region from the promoter of CotC to CotC, PCotC-huPTH1R-CotC DNA. 
The bottom strand represents the DNA sequencing results using the primer seq-huPTH1R 
CotC-R5 (5’-GATCTCAGCTTGTACCTCGCCATTGC-3’). Nucleotide 641 is the start 


















Figure A.8  DNA sequencing results of pDG1730 huPTH1R-CotC. (B) DNA sequencing 
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Figure B.1  Genomic DNA sequencing results of integration of pDG1730 
huPTH1R-CotC. (A) Top strand is the DNA coding region from the promoter of CotC to 
CotC, PCotC-huPTH1R-CotC DNA. The bottom strand represents the genomic DNA 
sequencing results using the primer seq-huPTH1R CotC-F1 (5’-TATGCCGCGATTTCC 
AATGAGG -3’). Nucleotide 1 is the start of PCotC and 2735 is end of CotC. This 













Figure B.1  Genomic DNA sequencing results of integration of pDG1730 
huPTH1R-CotC. (B) Genomic DNA sequencing traces were done with the primer 



















Figure B.2  Genomic DNA sequencing results of integration of pDG1730 
huPTH1R-CotC. (A) Top strand is the DNA coding region from the promoter of CotC to 
CotC, PCotC-huPTH1R-CotC DNA. The bottom strand represents the genomic DNA 
sequencing results using the primer seq-huPTH1R CotC-F2 (5’-GGCAAGCTTACAT 
AAGGAGGAACTACTATGGGCAGCAGCCATCATC-3’). Nucleotide 1 is the start of 



















Figure B.2  Genomic DNA sequencing results of integration of pDG1730 
huPTH1R-CotC. (B) Genomic DNA sequencing traces were done with the primer 









Figure B.3  Genomic DNA sequencing results of integration of pDG1730 
huPTH1R-CotC. (A) Top strand is the DNA coding region from the promoter of CotC to 
CotC, PCotC-huPTH1R-CotC DNA. The bottom strand represents the genomic DNA 
sequencing results using the primer seq-huPTH1R CotC-F3 (5’-CACAACAGGACGTG 
GGCCAACTACAG-3’). Nucleotide 1 is the start of PCotC and 2375 is end of CotC. This 


















Figure B.3  Genomic DNA sequencing results of integration of pDG1730 
huPTH1R-CotC. (B) Genomic DNA sequencing traces were done with the primer 



















Figure B.4  Genomic DNA sequencing results of integration of pDG1730 
huPTH1R-CotC. (A) Top strand is the DNA coding region from the promoter of CotC to 
CotC, PCotC-huPTH1R-CotC DNA. The bottom strand represents the genomic DNA 
sequencing results using the primer seq-huPTH1R CotC-F4 (5’-GGCCACCAACTACTA 
CTGGATTCTGG-3’). Nucleotide 1 is the start of PCotC and 2375 is end of CotC. This 




















Figure B.4  Genomic DNA sequencing results of integration of pDG1730 
huPTH1R-CotC. (B) Genomic DNA sequencing traces were done with the primer 












Figure B.5  Genomic DNA sequencing results of integration of pDG1730 
huPTH1R-CotC. (A) Top strand is the DNA coding region from the promoter of CotC to 
CotC, PCotC-huPTH1R-CotC DNA. The bottom strand represents the genomic DNA 
sequencing results using the primer seq-huPTH1R CotC-F5 (5’-GCAATGGCGAGGTA 
CAAGCTGAGATC-3’). Nucleotide 1 is the start of PCotC and 2735 is end of CotC. This 









Figure B.5  Genomic DNA sequencing results of integration of pDG1730 
huPTH1R-CotC. (B) Genomic DNA sequencing traces were done with the primer 









Figure B.6  Genomic DNA sequencing results of integration of pDG1730 
huPTH1R-CotC. (A) Top strand is the DNA coding region from the promoter of CotC to 
CotC, PCotC-huPTH1R-CotC DNA. The bottom strand represents the genomic DNA 
sequencing results using the primer seq-huPTH1R CotC-R2 (5'-CGGCTCGAGCATGAC 
TGTCTCCCACTCTTCC-3'). Nucleotide 1 is the start of PCotC and 2735 is end of CotC. 


















Figure B.6  Genomic DNA sequencing results of integration of pDG1730 
huPTH1R-CotC. (B) Genomic DNA sequencing traces were done with the primer 









Figure B.7  Genomic DNA sequencing results of integration of pDG1730 
huPTH1R-CotC. (A) Top strand is the DNA coding region from the promoter of CotC to 
CotC, PCotC-huPTH1R-CotC DNA. The bottom strand represents the genomic DNA 
sequencing results using the primer seq-huPTH1R CotC-R4 (5'-CCAGAATCCAGTAGT 
AGTTGGTGGCC-3'). Nucleotide 1 is the start of PCotC and 2735 is end of CotC. This 


















Figure B.7  Genomic DNA sequencing results of integration of pDG1730 
huPTH1R-CotC. (B) Genomic DNA sequencing traces were done with the primer 









Figure B.8  Genomic DNA sequencing results of integration of pDG1730 
huPTH1R-CotC. (A) Top strand is the DNA coding region from the promoter of CotC to 
CotC, PCotC-huPTH1R-CotC DNA. The bottom strand represents the genomic DNA 
sequencing results using the primer seq-huPTH1R CotC-R5 (5'-GATCTCAGCTTGTAC 
CTCGCCATTGC-3'). Nucleotide 1 is the start of PCotC and 2735 is end of CotC. This 


















Figure B.8  Genomic DNA sequencing results of integration of pDG1730 
huPTH1R-CotC. (B) Genomic DNA sequencing traces were done with the primer 
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